File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Quetiapine v. lithium in the maintenance phase following a first episode of mania: Randomised controlled trial

TitleQuetiapine v. lithium in the maintenance phase following a first episode of mania: Randomised controlled trial
Authors
Issue Date2017
Citation
British Journal of Psychiatry, 2017, v. 210, n. 6, p. 413-421 How to Cite?
Abstract© The Royal College of Psychiatrists 2017. Background Lithium and quetiapine are considered standard maintenance agents for bipolar disorder yet it is unclear how their efficacy compares with each other. Aims To investigate the differential effect of lithium and quetiapine on symptoms of depression, mania, general functioning, global illness severity and quality of life in patients with recently stabilised first-episode mania. Method Maintenance trial of patients with first-episode mania stabilised on a combination of lithium and quetiapine, subsequently randomised to lithium or quetiapine monotherapy (up to 800 mg/day) and followed up for 1 year. (Trial registration: Australian and New Zealand Clinical Trials Registry - ACTRN12607000639426.) Results In total, 61 individuals were randomised. Within mixed-model repeated measures analyses, significant omnibus treatment6visit interactions were observed for measures of overall psychopathology, psychotic symptoms and functioning. Planned and post hoc comparisons further demonstrated the superiority of lithium treatment over quetiapine. Conclusions In people with first-episode mania treated with a combination of lithium and quetiapine, continuation treatment with lithium rather than quetiapine is superior in terms of mean levels of symptoms during a 1-year evolution.
Persistent Identifierhttp://hdl.handle.net/10722/265000
ISSN
2020 Impact Factor: 9.319
2020 SCImago Journal Rankings: 2.564
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBerk, Michael-
dc.contributor.authorDaglas, Rothanthi-
dc.contributor.authorDandash, Orwa-
dc.contributor.authorYücel, Murat-
dc.contributor.authorHenry, Lisa-
dc.contributor.authorHallam, Karen-
dc.contributor.authorMacneil, Craig-
dc.contributor.authorHasty, Melissa-
dc.contributor.authorPantelis, Christos-
dc.contributor.authorMurphy, Brendan P.-
dc.contributor.authorKader, Linda-
dc.contributor.authorDamodaran, Saji-
dc.contributor.authorWong, Michael T.H.-
dc.contributor.authorConus, Philippe-
dc.contributor.authorRatheesh, Aswin-
dc.contributor.authorMcGorry, Patrick D.-
dc.contributor.authorCotton, Sue M.-
dc.date.accessioned2018-11-08T01:35:32Z-
dc.date.available2018-11-08T01:35:32Z-
dc.date.issued2017-
dc.identifier.citationBritish Journal of Psychiatry, 2017, v. 210, n. 6, p. 413-421-
dc.identifier.issn0007-1250-
dc.identifier.urihttp://hdl.handle.net/10722/265000-
dc.description.abstract© The Royal College of Psychiatrists 2017. Background Lithium and quetiapine are considered standard maintenance agents for bipolar disorder yet it is unclear how their efficacy compares with each other. Aims To investigate the differential effect of lithium and quetiapine on symptoms of depression, mania, general functioning, global illness severity and quality of life in patients with recently stabilised first-episode mania. Method Maintenance trial of patients with first-episode mania stabilised on a combination of lithium and quetiapine, subsequently randomised to lithium or quetiapine monotherapy (up to 800 mg/day) and followed up for 1 year. (Trial registration: Australian and New Zealand Clinical Trials Registry - ACTRN12607000639426.) Results In total, 61 individuals were randomised. Within mixed-model repeated measures analyses, significant omnibus treatment6visit interactions were observed for measures of overall psychopathology, psychotic symptoms and functioning. Planned and post hoc comparisons further demonstrated the superiority of lithium treatment over quetiapine. Conclusions In people with first-episode mania treated with a combination of lithium and quetiapine, continuation treatment with lithium rather than quetiapine is superior in terms of mean levels of symptoms during a 1-year evolution.-
dc.languageeng-
dc.relation.ispartofBritish Journal of Psychiatry-
dc.titleQuetiapine v. lithium in the maintenance phase following a first episode of mania: Randomised controlled trial-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1192/bjp.bp.116.186833-
dc.identifier.pmid28254958-
dc.identifier.scopuseid_2-s2.0-85020123073-
dc.identifier.volume210-
dc.identifier.issue6-
dc.identifier.spage413-
dc.identifier.epage421-
dc.identifier.eissn1472-1465-
dc.identifier.isiWOS:000402924200009-
dc.identifier.issnl0007-1250-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats